159 related articles for article (PubMed ID: 15111318)
1. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.
Yokoo H; Nobusawa S; Takebayashi H; Ikenaka K; Isoda K; Kamiya M; Sasaki A; Hirato J; Nakazato Y
Am J Pathol; 2004 May; 164(5):1717-25. PubMed ID: 15111318
[TBL] [Abstract][Full Text] [Related]
2. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
3. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype?
Tanaka Y; Yokoo H; Komori T; Makita Y; Ishizawa T; Hirose T; Ebato M; Shibahara J; Tsukayama C; Shibuya M; Nakazato Y
Acta Neuropathol; 2005 Jul; 110(1):39-47. PubMed ID: 15906048
[TBL] [Abstract][Full Text] [Related]
4. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
[TBL] [Abstract][Full Text] [Related]
5. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
6. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
7. Oligodendroglial markers in the cuprizone model of CNS de- and remyelination.
Salinas Tejedor L; Gudi V; Kucman V; Pul R; Gingele S; Sühs KW; Stangel M; Skripuletz T
Histol Histopathol; 2015 Dec; 30(12):1455-64. PubMed ID: 26110560
[TBL] [Abstract][Full Text] [Related]
8. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology.
Ikota H; Kinjo S; Yokoo H; Nakazato Y
Acta Neuropathol; 2006 May; 111(5):475-82. PubMed ID: 16598485
[TBL] [Abstract][Full Text] [Related]
9. Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas.
Okada M; Yano H; Hirose Y; Nakayama N; Ohe N; Shinoda J; Iwama T
Brain Tumor Pathol; 2011 Apr; 28(2):157-61. PubMed ID: 21312066
[TBL] [Abstract][Full Text] [Related]
10. Directing human neural stem/precursor cells into oligodendrocytes by overexpression of Olig2 transcription factor.
Maire CL; Buchet D; Kerninon C; Deboux C; Baron-Van Evercooren A; Nait-Oumesmar B
J Neurosci Res; 2009 Nov; 87(15):3438-46. PubMed ID: 19739249
[TBL] [Abstract][Full Text] [Related]
11. Genetic fate mapping of Olig2 progenitors in the injured adult cerebral cortex reveals preferential differentiation into astrocytes.
Tatsumi K; Takebayashi H; Manabe T; Tanaka KF; Makinodan M; Yamauchi T; Makinodan E; Matsuyoshi H; Okuda H; Ikenaka K; Wanaka A
J Neurosci Res; 2008 Dec; 86(16):3494-502. PubMed ID: 18816798
[TBL] [Abstract][Full Text] [Related]
12. Olig2-expressing progenitor cells preferentially differentiate into oligodendrocytes in cuprizone-induced demyelinated lesions.
Islam MS; Tatsumi K; Okuda H; Shiosaka S; Wanaka A
Neurochem Int; 2009; 54(3-4):192-8. PubMed ID: 19070638
[TBL] [Abstract][Full Text] [Related]
13. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
Hirose T; Ishizawa K; Shimada S
Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat.
Kolenda-Roberts HM; Harris N; Singletary E; Hardisty JF
Toxicol Pathol; 2013 Jan; 41(1):98-108. PubMed ID: 22821367
[TBL] [Abstract][Full Text] [Related]
15. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas.
Ohnishi A; Sawa H; Tsuda M; Sawamura Y; Itoh T; Iwasaki Y; Nagashima K
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1052-9. PubMed ID: 14575240
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function of Olig transcription factors enhances oligodendrogenesis and myelination.
Maire CL; Wegener A; Kerninon C; Nait Oumesmar B
Stem Cells; 2010 Sep; 28(9):1611-22. PubMed ID: 20672298
[TBL] [Abstract][Full Text] [Related]
17. Olig2-positive cells in glioneuronal tumors show both glial and neuronal characters: the implication of a common progenitor cell?
Matsumura N; Yokoo H; Mao Y; Yin W; Nakazato Y
Neuropathology; 2013 Jun; 33(3):246-55. PubMed ID: 23025580
[TBL] [Abstract][Full Text] [Related]
18. Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation.
Samanta J; Kessler JA
Development; 2004 Sep; 131(17):4131-42. PubMed ID: 15280210
[TBL] [Abstract][Full Text] [Related]
19. Low grade diffuse gliomas: shared cellular composition and morphometric differences.
Kinjo S; Hirato J; Nakazato Y
Neuropathology; 2008 Oct; 28(5):455-65. PubMed ID: 18282166
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors.
Aguirre-Cruz L; Mokhtari K; Hoang-Xuan K; Marie Y; Criniere E; Taillibert S; Lopes M; Delattre JY; Sanson M
J Neurooncol; 2004 May; 67(3):265-71. PubMed ID: 15164981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
